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Developing scandium and yttrium coordination
chemistry to advance theranostic
radiopharmaceuticals
Korey P. Carter1,5, Gauthier J.-P. Deblonde 1,2,5, Trevor D. Lohrey1,3, Tyler A. Bailey1,4, Dahlia D. An 1,
Katherine M. Shield1,4, Wayne W. Lukens Jr.1 & Rebecca J. Abergel1,4✉
The octadentate siderophore analog 3,4,3-LI(1,2-HOPO), denoted 343-HOPO hereafter, is
known to have high affinity for both trivalent and tetravalent lanthanide and actinide cations.
Here we extend its coordination chemistry to the rare-earth cations Sc3+ and Y3+ and
characterize fundamental metal–chelator binding interactions in solution via UV-Vis spec-
trophotometry, nuclear magnetic resonance spectroscopy, and spectrofluorimetric metal-
competition titrations, as well as in the solid-state via single crystal X-ray diffraction. Sc3+ and
Y3+ binding with 343-HOPO is found to be robust, with both high thermodynamic stability
and fast room temperature radiolabeling, indicating that 343-HOPO is likely a promising
chelator for in vivo applications with both metals. As a proof of concept, we prepared a 86Y-
343-HOPO complex for in vivo PET imaging, and the results presented herein highlight the
potential of 343-HOPO chelated trivalent metal cations for therapeutic and theranostic
applications.
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Nuclear medicine is a rapidly growing field based upon theclinical use of radionuclides for diagnostic and ther-apeutic purposes1. Positron emission tomography (PET)
and single-photon emission computed tomography (SPECT) are
two of the most common imaging modalities for diagnostic
purposes, while targeted-radionuclide therapeutic efforts focus on
inducing irreversible DNA damage via the emission of either α-
particles, β− particles, or low-energy (Auger) electrons2. The full
potential of nuclear medicine may be realized with theranostics,
wherein a molecular targeting vector is labeled with both a diag-
nostic and a therapeutic radionuclide that are utilized for con-
comitant imaging and treatment3–6. Ideally, the employed
radionuclides are a matched pair, where both are radioisotopes of
the same chemical element; however, very few elements have
isotope pairs with suitable nuclear decay properties. As a result,
current efforts focus on perceived chemical homologs such as
68Ga as the PET imaging agent mimic of 177Lu or 90Y for β−
therapy. However, this approach is hindered by the different ionic
radii of these elements (CN= 6, 0.62 Å for Ga3+; CN= 8, 0.977 Å
for Lu3+; CN= 8, 1.019 Å for Y3+)7,8, which leads to mismatches
in coordination chemistry and varying in vivo behavior9–11. The
identification of chemically identical (i.e., isotopic) pairs of
radionuclides with complementary nuclear properties is valuable
for the development of new theranostic agents, and 44Sc/47Sc and
86Y/90Y are two pairs with great promise in this arena1,12–14.
Both 44Sc and 86Y offer several advantages compared to the
commonly utilized 68Ga as diagnostic pairs for 177Lu or 90Y,
including longer half-lives (3.97 and 14.74 h, respectively), higher
resolution PET images (Supplementary Table 2), and preferences for
higher coordination numbers15,16. The latter is of particular impor-
tance as the current gold standard for metal ion chelation in nuclear
medicine is the octadentate ligand 1,4,7,10-tetraazocyclododecane-
1,4,7,10-tetraacetic acid (DOTA). Despite its frequent use as a
radionuclide chelator for preclinical and clinical applications, DOTA
has a number of limitations, including poor binding kinetics, which
generally necessitate heating for radiochemical complexation17–19.
An ideal chelator for theranostic applications would feature fast
radiolabeling kinetics at room temperature, low toxicity, and in vivo
stability (i.e., kinetic and thermodynamic inertness), and ligands
featuring hydroxypyridinone moieties are known to meet these
criteria20,21. The octadentate siderophore analog, 3,4,3-LI(1,2-
HOPO), denoted 343-HOPO hereafter, is known to satisfy all three
criteria described above, and is an especially effective theranostic
chelator due to its propensity to bind with both trivalent and tetra-
valent metal cations22,23. In addition, density functional theory cal-
culations have highlighted structural deformities for 343-HOPO
complexes with endogenous metals, which minimizes in vivo com-
petition for the rare-earth cations (Sc3+, Y3+) included in 343-
HOPO chelates herein24.
Here we begin our investigations by looking at fundamental
Sc3+-343-HOPO and Y3+-343-HOPO binding interactions in
solution via UV-Vis spectrophotometry, nuclear magnetic reso-
nance (NMR) spectroscopy, and spectrofluorimetric metal-
competition titrations, and in the solid-state via single crystal
X-ray diffraction. Subsequently, we conduct proof-of-concept in
vivo PET imaging with a 86Y-343-HOPO complex. 86Y was
selected over 44Sc for PET studies as 86Y3+ is a matched pair with
90Y and a better chemical match than either Ga3+ or Sc3+ as a
diagnostic partner to 177Lu, both of which (90Y and 177Lu) are β−
emitting isotopes included in treatments approved by the U.S.
Food and Drug Administration25,26. Moreover, while Sc3+ and
Y3+ are similar in hardness, with IA values of 10.49 and 10.64,
respectively, they differ greatly in pKa values (4.3 for Sc3+ v. 7.7
for Y3+)1. This manifests in the pH where hydrolysis begins for
the two rare-earth cations, with Sc3+ hydrolysis beginning at
approximately pH 2.5 while Y3+ hydrolysis occurs at neutral pH
or above27–29. This latter characteristic is desirable for radi-
olabeling processes, which typically require pH values between 4
and 5, where hydrolysis products in a Sc3+ system may limit the
efficacy of a selected chelator30. Finally, the longer half-life of 86Y
(t1/2= 14.74 h) covers a much longer portion (~2 days) of the
pharmacokinetics of relevant therapeutic targeting vectors com-
pared to either 68Ga (t1/2= 1.13 h) or 44Sc (t1/2= 3.97 h), which is
a significant advantage as the latter PET isotopes are limited to
measuring only early therapeutic uptake kinetics31.
Results and discussion
Solution chemistry of rare earth complexes with 343-HOPO.
The UV-Visible absorbance spectra of 343-HOPO at pH 7.4 upon
addition of Sc3+ or Y3+ are shown in Fig. 1. Compared to free
Fig. 1 UV-Vis absorbance spectra of [Sc-343-HOPO]− and [Y-343-HOPO]−. Samples contained 30 μM of 343-HOPO (black curve), 30 μM of 343-
HOPO and 30 μM of Sc3+ ions (pink curve), or 30 μM of 343-HOPO and 30 μM of Y3+ ions (green curve). Path length: 10 mm. Background electrolyte:
25 mM HEPES buffer, pH= 7.4. Absorbance corrected from blank absorbance (25mM HEPES). T= 25 °C.
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343-HOPO, the UV spectrum is blue shifted upon addition of the
metal ions Sc3+ and Y3+, which do not absorb in the highlighted
spectral window. Changes in UV-Vis spectra are due to the
binding of Sc3+ or Y3+ ions to the 1,2-HOPO groups of the
chelator, and such results are consistent with those previously
reported for the binding of lanthanide ions (Ln3+, Ln= La3+ to
Lu3+) to 343-HOPO and other 1,2-HOPO chelators22,32,33. The
results depicted in Fig. 1 suggest that at physiological pH and at
high metal concentrations, compared to radiopharmaceutical
formulations, one equivalent of 343-HOPO is sufficient to form
stable complexes with Sc3+ or Y3+ and prevent metal ion
hydrolysis. Further confirmation of 343-HOPO complex stability
can be seen in the 45Sc NMR spectrum (Supplementary Fig. 1)
where the [Sc-343-HOPO]− chemical shift is observed downfield
at ca. 62.5 ppm. The Sc3+-aqua ion in dilute HCl produces a
sharp signal at ca. 4 ppm (Supplementary Fig. 1), and the large
45Sc chemical shift upon complexation indicates 343-HOPO
effectively shields the 45Sc nucleus from solvent molecules (vide
infra)13. The single peak in the 45Sc NMR spectrum for [Sc-343-
HOPO]− also suggests no metal-centered isomerism on the NMR
timescale, consistent with only a single species in solution.
Based on the solution thermodynamics of Ln3+ complexes with
343-HOPO22,34,35, the complexes that are likely formed in aqueous
solutions with Sc3+ and Y3+ are: [M-343-HOPOH], [M-343-
HOPO]−, and [M-343-HOPO(OH)]2− (where M= Sc3+ or Y3+).
The protonated and hydroxylated complexes, [M-343-HOPOH]
and [M-343-HOPO(OH)]2-, are only present in relatively narrow
pH ranges for Ln3+ cations (0 < pH < 3 and 9 < pH < 11, respec-
tively), thus the most relevant complex at physiological pH (7.4) is
[M-343-HOPO]−. By analogy, the complexes [Sc-343-HOPO]−
and [Y-343-HOPO]− are expected to be the predominant species in
the pH range 3 to 9 (Supplementary Fig. 2). The proton-
independent stability constants (log βmlh) for both complexes were
determined via spectrofluorimetric metal-competition titration
Fig. 2 Spectrofluorimetric metal competition titrations. [Eu-343-HOPO]− was competed against Sc3+ (a) and Y3+ (b). Insets: Emission intensity at
612 nm versus the ratio M/Eu (M= Sc3+ or Y3+). Ratio M/Eu= 0 to 20 equivalents. Background electrolyte: 2.5 mM HEPES+ KCl. I= 0.1 M. pH= 7.4.
T= 25°C.
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using the luminescent [Eu-343-HOPO]− complex as a reference22.
Upon excitation at 325 nm, the europium complex exhibits an
intense emission spectrum in the spectral window 500–800 nm.
When another metal that competes with Eu3+ for 343-HOPO
binding is added to the system, the intensity of the emission
spectrum of [Eu-343-HOPO]− decreases based on Eq. (1).
Eu 343HOPO½ aqð ÞþM3þaqð Þ ¼ M 343HOPO½ aqð ÞþEu3þaqð Þ
ð1Þ
This equation can be applied if the competing M3+ ions (here
Sc3+ and Y3+) do not form a luminescent complex with 343-
HOPO or generate an emission spectrum different from that of
[Eu-343-HOPO]−. 343-HOPO complexes of Sc3+ and Y3+ are
not luminescent; consequently, upon addition of Sc3+ and Y3+ to
a [Eu-343-HOPO]− solution, the emission intensity decreases
until the concentration of [Eu-343-HOPO]− in the system is
undetectable due to the formation of the spectroscopically silent
[Sc-343-HOPO]− or [Y-343-HOPO]−. Examples of this type of
spectroscopic titration with both Sc3+ and Y3+ are shown in
Fig. 2.
Utilizing the known metal hydrolysis constants, ligand protona-
tion constants, and log β110 value of [Eu-343-HOPO]− 22,34, proton-
independent stability constants values for [Sc-343-HOPO]− and
[Y-343-HOPO]− were obtained using the method described above.
Deconvolution of titration data were performed with HypSpec34,36,
which yielded log β110 values of 25.16 ± 0.01 and 20.76 ± 0.09 for
[Sc-343-HOPO]− and [Y-343-HOPO]−, respectively. Notably, [Sc-
343-HOPO]− is the most stable trivalent-343-HOPO complex
reported to date, with a log β110 value three orders of magnitude
higher than its closest lanthanide or actinide analog (Table 1).
Structural chemistry of rare earth complexes with 343-HOPO.
While the solution chemistry of 343-HOPO and its use in a variety
of applications such as actinide decorporation and separa-
tions37,38, post-MRI chelation therapy39, or 89Zr PET imaging40 is
increasingly well-characterized, the structural chemistry of this
chelator, with trivalent metals in particular, remains largely
unexplored. Daumann et al. reported the first crystal structure
featuring 343-HOPO and Eu3+ in 201541, and this remained the
only published structure featuring 343-HOPO and a trivalent
metal until this study. Our group has made progress recently on
the structural chemistry of 343-HOPO with tetravalent p-block
and d-block metals42,43, and here we extend this knowledge to
systems featuring Sc3+ and Y3+. Both complexes 1, K[Sc(343-
HOPO)]•DMF•(H2O)x, and 2, K[Y(343-HOPO)]•DMF, crystal-
lize in the space group P-1 upon slow evaporation from solutions
of methanol containing 5% DMF. Complexes 1 and 2 both feature
a single crystallographically unique rare-earth metal center with
the Sc3+ and Y3+ cations adopting distorted square antiprismatic
molecular geometries (Fig. 3). Sc3+ and Y3+ cations are each eight
coordinate with all four 1,2-HOPO moieties of 343-HOPO
binding in a bidentate manner and the average Sc3+ and
Y3+–O bond distances are 2.213 Å and 2.347 Å, respectively. The
asymmetric units for both complexes feature potassium cations for
charge balancing purposes, as well as solvent molecules, which are
significantly disordered for complex 1. Akin to other examples of
crystallographically characterized metal complexes of 343-HOPO,
we find the Sc3+ and Y3+ complexes (1 and 2) display handed-
ness, as racemic mixtures of Δ(λ) and Λ(δ) isomers. This notation,
which we have previously employed, describes the configuration of
the 1,2-HOPO moieties surrounding the metal center as either Δ
or Λ, and the relative configuration of the butylene diamine
backbone as either λ or δ (Supplementary Fig. 3)43. We have
proposed that the extremely high thermodynamic stabilities of
343-HOPO complexes may allow for the chromatographic
separation or resolution of these Δ(λ) and Λ(δ) enantiomers, and
while outside the scope of the current study, we are currently
working to achieve this goal and delineate differing in vivo
behaviors that result due to complex handedness43.
343-HOPO complexation with 86Y and in vivo imaging
experiments. An advantage of working with 343-HOPO is that it
has been evaluated for potential biomedical applications; thus,
toxicology and pharmacology studies have already been com-
pleted44–46. In addition, the in vivo stability of metal complexes of
343-HOPO formed with both trivalent (Eu, Am, Cm) and tet-
ravalent (Zr, Pu) metals has been investigated in multiple studies,
using ex vivo radioanalytical techniques and in vivo PET imaging.
All of these biodistribution studies have highlighted the unusual
in vivo stability and quantitative, rapid hepatobiliary clearance of
343-HOPO complexes, as well as minimal or undetectable non-
targeted uptake of metal ions, when compared to other com-
monly used chelators, including diethylenetriaminepentaacetic
acid (DTPA) and desferrioxamine B (DFO)22,37,40,47. To assess
the in vivo behavior and pharmacokinetics of the 86Y-343-HOPO
complex, we administered the radiolabeled small molecule com-
plex to young adult female Swiss Webster mice via intravenous
injection. Mice were imaged at 15 min, 2 h, 24 h, and 48 h post-
injection, and the results are highlighted in Fig. 4, Supplementary
Fig. 4, and Supplementary Table 4, largely confirming biodis-
tribution patterns previously noted with other metal ions. At
15 min, the vast majority of the radioactivity is observed in the
gall bladder and gastrointestinal tract, indicating hepatic clear-
ance is the main excretion pathway for 86Y-343-HOPO, with a
small amount of activity appearing in the bladder, suggesting a
minor renal clearance pathway as well. This is confirmed at 2 h
when the majority of remaining radioactivity is found in the
gastrointestinal tract and the liver. At 24 and 48 h, very little
detectable radioactivity remains (Fig. 4, Supplementary Fig. 4, and
Supplementary Table 4), which suggests the pharmacokinetics of
the 86Y-343-HOPO complex are rapid. PET images at all four
time points also display minimal kidney uptake, an important
feature that may prevent dose-limiting nephrotoxicity (Fig. 4,
Supplementary Fig. 4, and Supplementary Table 4), in contrast to
86Y complexes formed with DOTA or DTPA48. Moreover, the
Table 1 Summary of proton-independent stability constants
with 343-HOPO and trivalent metal cations.
Cation log β110 Reference(s)
Sc3+ 25.16 ± 0.01 this work
Y3+ 20.76 ± 0.09 this work
La3+ 16.4(3) 22
Ce3+ 17.4(5) 35
Pr3+ 18.2(4) 22
Nd3+ 18.7(1) 22
Sm3+ 19.7(3) 22
Eu3+ 20.2(2) 22, 34
Gd3+ 20.5(1) 22
Tb3+ 20.9(1) 22
Dy3+ 21.2(1) 22
Ho3+ 21.5(1) 22
Er3+ 21.7(1) 22
Tm3+ 22.0(1) 22
Yb3+ 22.2(1) 22
Lu3+ 21.2(1) 22
Am3+ 20.4(2) 54
Cm3+ 21.8(4) 47
Log β110 values, at 25°C and I= 0.1 M, either experimentally determined in this work or
previously reported22,34,35,47,54.
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lack of radioactivity accumulating in the skeleton or other organs
suggests that the 86Y complex remains intact over several hours
in vivo12, thereby demonstrating that 343-HOPO is well suited
for targeted in vivo applications with yttrium radioisotopes.
Herein, we characterized the complexation of Sc3+ and Y3+
with 343-HOPO in solution via UV-Vis spectrophotometry, NMR
spectroscopy, and spectrofluorimetric metal-competition titra-
tions, and in the solid-state via single crystal X-ray diffraction. We
experimentally observed high thermodynamic stability for the
binding of 343-HOPO with Sc3+ and Y3+, and crystallographic
analysis agrees with solution-state NMR results, indicating rare-
earth cations are well shielded from solvent molecules. Proof of
concept 86Y-343-HOPO PET imaging experiments revealed
hepatic clearance, rapid pharmacokinetics, and no detectable
radioactivity accumulating in bones or other organs, all of which
are valuable for future work pairing 86Y with therapeutic isotopes
Fig. 3 Solid-state structures of Sc3+-343-HOPO and Y3+-343-HOPO complexes. Polyhedral representations of complexes 1 and 2, where pink and green
polyhedra are Sc3+ and Y3+ centers, respectively, and spheres represent oxygen atoms (red) and nitrogen atoms (blue). Hydrogen atoms, potassium
cations, and solvent molecules are omitted for clarity.
Fig. 4 Coronal PET images of 86Y-343-HOPO. Three healthy mice were administered 86Y-343-HOPO (93.1 µCi [3.44 MBq] in 10x PBS) via tail vein
injection and imaged between 15 min and 24 h after injection. The gall bladder (a), the gastrointestinal tract (b), and the bladder (c) can be visualized at the
15 min timepoint. The 86Y-343-HOPO complex primarily undergoes rapid hepatic clearance and no uptake of 86Y in the skeleton is observed.
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of interest. In combination, these results indicate that 343-HOPO
is likely a promising chelator for both the 44/47Sc and 86/90Y
theranostic isotope pairs. Future studies will focus on expanding
efforts to 343-HOPO conjugates49 and siderocalin fusion pro-
teins50,51 using Sc3+ and Y3+, as well as lanthanides and actinides
of theranostic interest.
Methods
Incremental spectrofluorimetric titrations. The spectrofluorimetric metal-metal
competition titration method developed by Sturzbecher-Hoehne et al.22 was used
to evaluate the thermodynamic stability of the Sc(III)-343-HOPO and Y(III)-343-
HOPO complexes. This method used the luminescent [Eu-343-HOPO]− complex
as a reference as this complex has been thoroughly characterized34,41, and typi-
cally, 10–12 samples of 2 mL were prepared per titration. Each sample contained
0.1 µM Eu(III), 0.1 µM 343-HOPO, and 0 to 20 equivalents of competing
metal ions (here Sc3+ or Y3+). Samples were buffered with 0.1 M HEPES at pH
7.4, and after 24 h of equilibration in a thermostated bath at 25 °C, the emission
spectra of the samples were acquired with a HORIBA Jobin Yvon IBH FluoroLog-
3 spectrofluorimeter in steady state mode. Emission (550–725 nm–350 data
points) was monitored perpendicular to the excitation pulse after excitation of the
sample at 325 nm. Slits were set at 2.0 nm and 1.0 nm for the emission and
excitation monochromators, respectively, and the integration time was 0.4 s
per point.
343-HOPO radiolabeling with 86Y. A 2.86 mL 10× phosphate buffered saline
(PBS) solution containing 5 µL of 343-HOPO (34.9 µM) in DMSO was added to
the 86Y stock solution in 0.1 M HCl. To minimize radioactivity dose, the solution
was not shaken and was instead allowed to equilibrate at room temperature inside a
lead pig for 10 min. 86Y-343-HOPO binding was confirmed via a wild-type side-
rocalin (Scn) binding assay developed in-house, wherein an aliquot of 86Y-343-
HOPO complex was combined with Scn, and upon Scn recognition, separation
from free 86Y was done via spin filtration52. This technique has been established for
charge-based separation of neighboring actinides, and was adapted here to quali-
tatively confirm 86Y complexation by 343-HOPO, with characterization done using
an optimized Ludlum 2224-1 Alpha-Beta Scaler-Ratemeter53. An aliquot was also
taken to determine the activity via γ-spectroscopy, wherein the 307.00, 443.13,
580.57, and 777.37 keV gamma lines of 86Y were measured on a P-Type High
Purity Germanium γ-Spectrometer.
Small animal PET imaging. All procedures and protocols used in small animal
PET imaging studies were reviewed and approved by the Institutional Animal Care
and Use Committee at Lawrence Berkeley National Laboratory. Experiments were
performed in compliance with guidelines from the Association for Assessment and
Accreditation of Laboratory Animal Care International (AAALAC) in AAALAC
accredited facilities. The animals used were healthy young adult (11–12 weeks old)
female (32.6 ± 1.5 g) Swiss Webster mice (Simonsen Laboratories, Gilroy, CA,
USA), which were given water and food ad libitum, and kept under a 12-h light
cycle with controlled temperature (18–22 °C) and relative humidity (30–70%).
Intravenous (iv) injections into a warmed lateral tail vein were performed under
isoflurane anesthesia. Three mice were injected iv with a single 200 µL dose of 86Y-
343-HOPO (3.44 MBq, 93.1 μCi, 2.18 nM), the preparation of which is described
above. The mice were imaged at 15 min, 2 h, 24 h, and 48 h after injection on a
Concorde microPET R4 which supports a transaxial resolution of 1.66 mm
FWHM, in the head first supine position. During the scan, mice were anesthetized
with a mixture of isoflurane and oxygen. An energy window of 350− 650 keV and
a coincidence timing window of 6 ns were used during image acquisition. Mice
were subsequently euthanized under isoflurane anesthesia via cervical dislocation
following the 48-h time point.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Additional experimental details (see Supplementary Methods), as well as X-ray
crystallographic files in CIF format, ORTEP figures of both complexes, and additional
figures and tables are included in the supplementary information. All data generated or
analyzed during this study are included in this published article (or in the supplementary
information). CCDC 1983231 and 1983232 contain the supplementary crystallographic
information for each complex, which can be obtained free of charge from The Cambridge
Crystallographic Data Center. The supplementary crystallographic information is also
available as Supplementary Data 1 and 2.
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